Half-life is one of the most frequently cited specifications in peptide research — and one of the most frequently misunderstood. It is often treated as a measure of how long a compound "works," when in fact it describes something much narrower: how quickly a compound disappears.
Peptide half-life (t½) is the time required for a compound's concentration to fall by 50%. It measures clearance rate only. Most unmodified peptides clear within minutes due to peptidase degradation and renal filtration, while long-acting compounds use structural modifications — albumin binding, acylation, PEGylation — to persist for hours or days.
On this page
What Peptide Half-Life Actually Measures
Half-life, written as t½, is the time required for the concentration of a compound in a given compartment — usually plasma — to fall to half its starting value. If a peptide has a measured half-life of 30 minutes, then 30 minutes after peak concentration roughly half remains, after an hour roughly a quarter, and so on.
Most peptides follow approximately first-order elimination, meaning a constant fraction is removed per unit time rather than a constant amount. The result is a predictable decay curve that flattens as it falls.
This is why researchers commonly treat four to five half-lives as the point at which a compound is functionally cleared from the system being measured — a useful reference when setting washout intervals between experimental conditions.
Distribution vs. terminal half-life
Published figures often refer to different phases of the same curve. After administration in an in vivo model, concentration falls steeply as the compound distributes out of circulation into tissue (the distribution phase), then declines more gradually as it is eliminated (the terminal phase). A single compound can therefore be reported with two very different half-lives depending on which phase was measured — one reason literature values for the same peptide sometimes appear to contradict each other.
Why Most Peptides Clear So Quickly
Unmodified peptides are, from a biological system's perspective, ordinary protein fragments — and there are well-developed mechanisms for taking them apart. Two dominate.
Enzymatic degradation. Plasma, kidney, and liver tissue contain peptidases that cleave peptide bonds at specific recognition sites. Exopeptidases trim residues from the N- or C-terminus; endopeptidases cut internal bonds. A linear peptide with exposed termini and no protective modifications presents multiple accessible cleavage points, and degradation can begin within minutes.
Renal filtration. The glomerulus filters small molecules efficiently. Compounds below roughly 5 kDa — which includes the large majority of research peptides, most falling between 500 Da and 4 kDa — pass into filtrate readily and leave circulation. Molecular size alone places a hard ceiling on how long a small unmodified peptide can persist.
Together these explain why native sequences such as GHK-Cu, Epitalon, and GHRH analogues are reported with half-lives measured in minutes rather than hours. It is not a defect in the compound; it is the default behaviour of a small peptide in a biological system.
What Makes a Peptide Long-Acting
Extending a peptide's half-life means interfering with one or both clearance routes. The strategies below appear consistently across preclinical and academic research literature.
| Modification | Mechanism | Typical effect on t½ |
|---|---|---|
| Albumin-binding group (DAC) | Binds the peptide to circulating serum albumin, forming a large complex that resists filtration and acts as a reservoir | Hours → days |
| Fatty-acid acylation | A lipid chain promotes reversible albumin association and slows absorption from the depot | Hours → days |
| PEGylation | Polyethylene glycol chains raise hydrodynamic radius above the renal filtration threshold and shield cleavage sites | Multi-fold increase |
| D-amino acid substitution | Peptidases recognise L-isomers; D-residues at cleavage sites block recognition | Minutes → hours |
| Cyclization | Removes free termini and constrains conformation, reducing exopeptidase access | Minutes → hours |
| Terminal capping | N-terminal acetylation or C-terminal amidation blocks exopeptidase entry points | Modest increase |
The clearest illustration is the GHRH analogue family. CJC-1295 without DAC is reported with a half-life on the order of 30 minutes. CJC-1295 with DAC is the same core sequence carrying a drug affinity complex that binds albumin — and literature reports its half-life in days. One structural addition, several orders of magnitude of difference in clearance.
Short-Acting vs. Long-Acting: How They Differ in Practice
Neither category is inherently superior. They suit different study designs, and the trade-offs are predictable.
| Parameter | Short-acting | Long-acting |
|---|---|---|
| Typical t½ | Minutes to a few hours | Many hours to several days |
| Concentration profile | Sharp peak, rapid decline — pulsatile | Flatter, sustained exposure |
| Washout between conditions | Fast; same-day crossover often feasible | Slow; washout may run days |
| Accumulation on repeat administration | Minimal | Accumulates until steady state |
| Sampling burden | High — dense early timepoints needed | Lower frequency, longer timeline |
| Best suited to | Acute-response and pulsatile-signalling protocols | Sustained-exposure and steady-state protocols |
Short half-life also means less margin for error in sample timing. If a compound clears in 20 minutes and the first draw is taken at 45, the peak has already been missed. Long-acting compounds forgive loose timing but demand patience at the other end — a washout covering five half-lives of a multi-day compound can occupy well over a week of study calendar.
Reported Half-Life Ranges for Commonly Studied Compounds
The figures below reflect ranges reported across published preclinical and academic literature. They vary considerably by species, model, route, assay method, and whether distribution or terminal phase was measured — treat them as orientation values, not specifications.
| Compound | Reported half-life range | Category |
|---|---|---|
| BPC-157 | Minutes; rapid plasma clearance in rodent models | Short-acting |
| GHK-Cu | Minutes; typically under one hour | Short-acting |
| Epitalon | Minutes; very rapid degradation reported | Short-acting |
| Sermorelin (GHRH 1-29) | ~10–15 minutes | Short-acting |
| Semax / Selank | Minutes in plasma | Short-acting |
| GHRP-6 | ~20–30 minutes | Short-acting |
| CJC-1295 no DAC | ~30 minutes | Short-acting |
| Tesamorelin | ~25–40 minutes | Short-acting |
| MOTS-c | Short; rapid clearance reported | Short-acting |
| Ipamorelin | ~2 hours | Intermediate |
| TB-500 (Thymosin β4 fragment) | ~2–3 hours | Intermediate |
| CJC-1295 with DAC | ~6–8 days | Long-acting |
Blends inherit the kinetics of their constituents rather than averaging them. Glow Blend, built around GHK-Cu, and KLOW Blend, which combines BPC-157, GHK-Cu, TB-500 and KPV, each contain components clearing on different schedules — worth accounting for when selecting sampling timepoints. Our guide to peptide blends covers that in more detail.
Every compound above is batch-tracked with third-party documentation — review current COAs here.
Pharmacokinetics Terms Worth Knowing
Half-life appears alongside several related parameters in published research. These are the ones most often encountered.
| Term | What it describes |
|---|---|
| t½ (half-life) | Time for concentration to fall by 50% |
| Cmax | The peak concentration reached after administration |
| Tmax | The time at which Cmax occurs |
| AUC | Area under the concentration-time curve — total exposure over time |
| Clearance (CL) | Volume of plasma cleared of compound per unit time |
| Vd | Volume of distribution — how widely the compound spreads beyond plasma |
| Bioavailability (F) | Fraction reaching circulation intact relative to intravenous reference |
| Steady state | Point at which input and clearance balance on repeat administration (~4–5 half-lives) |
| Washout | Interval allowed for clearance before a new condition begins |
| Flip-flop kinetics | Where absorption is slower than elimination, so the curve reflects absorption rate |
Three Things Half-Life Does Not Tell You
1. It does not tell you how long an effect lasts
Half-life describes concentration, not consequence. Research literature frequently documents downstream activity persisting well after a compound has largely cleared — receptor binding, signalling cascades, and gene-expression changes each run on their own timescales. Pharmacokinetics (what happens to the compound) and pharmacodynamics (what the compound initiates) are tracked as separate parameters for exactly this reason, and conflating them is the single most common half-life error in peptide research.
2. It does not tell you how stable the vial is
These are entirely different measurements. Half-life is clearance within a biological system; stability is degradation within a container. A compound that clears from plasma in ten minutes may remain intact as a lyophilized powder for a very long time under appropriate storage — and a long-acting compound handled poorly can degrade in the vial regardless of its kinetics. Lyophilized powder is substantially more stable than peptide in solution, which is why reconstitution timing matters. See our guide on how to store research peptides for the full breakdown.
3. It does not transfer cleanly between models
A half-life measured in rodent plasma is not a half-life in a different species, and an intravenous figure is not a subcutaneous one. Where absorption from a depot is slower than elimination, the measured curve reflects absorption rather than true clearance — the flip-flop kinetics scenario. Always check which model, route, and phase a published figure refers to before applying it to a protocol.
Applying Half-Life to Study Design
Once a compound's approximate clearance is known, several design decisions follow from it:
- Sampling schedule — short half-life compounds need dense early timepoints; long-acting compounds need a longer total window
- Washout intervals — four to five half-lives as a working reference between crossover conditions
- Steady state — repeated administration of a long-acting compound approaches steady state after roughly four to five half-lives
- Reconstitution planning — solution volumes and concentrations should match the protocol timeline; our peptide calculator handles the arithmetic
- Assay sensitivity — rapidly cleared compounds may fall below the detection limit faster than the assay can resolve
Frequently Asked Questions
What does peptide half-life mean?
Peptide half-life is the time required for the concentration of a peptide in a given system to fall by half. It measures clearance rate only, describing how quickly a compound is removed from a research model rather than how long any effect lasts.
Why do most research peptides have such short half-lives?
Unmodified peptides are broken down by circulating peptidases and filtered out by the kidneys because of their low molecular weight. Both processes act within minutes, which is why many native sequences show measured half-lives of under an hour.
What makes a peptide long-acting?
Structural modifications slow clearance. Approaches described in the literature include albumin-binding groups such as DAC, fatty-acid acylation, PEGylation, cyclization, terminal capping, and substitution of D-amino acids at cleavage sites.
What is the difference between CJC-1295 with DAC and without DAC?
They share the same core sequence. The DAC version carries a drug affinity complex that binds serum albumin, which resists renal filtration and extends the reported half-life from roughly 30 minutes to several days.
Is peptide half-life the same as shelf stability?
No. Half-life describes clearance inside a biological system, while shelf stability describes how long a compound stays intact in a vial. A peptide that clears in minutes can remain stable for long periods as a lyophilized powder.
How many half-lives until a peptide is cleared?
Researchers commonly treat four to five half-lives as the point of functional clearance. After four half-lives roughly 94 percent has been removed, and after five roughly 97 percent.
Key Takeaways
- Half-life is the time for concentration to fall by 50% — a clearance measurement, nothing more
- Four to five half-lives is the common working reference for functional clearance
- Small unmodified peptides clear in minutes due to peptidase activity and renal filtration
- Long-acting compounds rely on albumin binding, acylation, PEGylation, or D-amino acid substitution
- Half-life is distinct from vial stability and from duration of observed effect
- Published figures vary by species, route, and measurement phase — treat them as orientation values
Batch-Tested Research Compounds, Shipped Across Canada
Every batch verified by HPLC and mass spectrometry, individually documented, and shipped tracked from Ontario.
Browse the Research Catalogue